## ABSTRACT

Provided is a method of treating or ameliorating certain fibrotic diseases or other indications in an animal, including a human, comprising administering an effective amount of a compound of the formula I:

 $Y-Ar^{\oplus} \bullet X^{-}$  (I)

wherein:

5

10

15

20

25

30

35

40

45

- a. Ar is a five or six membered heteroaryl ring having a first ring nitrogen and optionally second or third ring nitrogens, with the remaining ring atoms being carbon, oxygen, or sulfur, provided the first nitrogen of Ar is a quaternary nitrogen and Ar is not thiazolium, oxazolium or imidazolium;
- **b.** Y is substituted on the first ring nitrogen, with the proviso that if Ar is pyrazole, indazole, (1,2,3)-triazole, benzotriazole, or (1,2,4)-triazole, the second ring nitrogen is substituted

c. Y is:

- 1. a group of the formula  $-CH(R^5)-R^6$  [as preferred in one embodiment]
  - (a) wherein R<sup>5</sup> is hydrogen, alkyl-, cycloalkyl-, alkenyl-, alkynyl-, aminoalkyl-, hydroxy[C<sub>1</sub> to C<sub>6</sub>]alkyl, dialkylaminoalkyl-, (N-[C<sub>6</sub> or C<sub>10</sub>]aryl)(N-alkyl)aminoalkyl-, piperidin-1-ylalkyl-, pyrrolidin-1-ylalkyl, azetidinylalkyl, 4-alkylpiperazin-1-ylalkyl, 4-alkylpiperidin-1-ylalkyl, 4-[C<sub>6</sub> or C<sub>10</sub>]arylpiperidin-1-ylalkyl, azetidin-1-ylalkyl, morpholin-4-ylalkyl, thiomorpholin-4-ylalkyl, piperazin-1-ylalkyl, piperidin-1-ylalkyl, [C<sub>6</sub> or C<sub>10</sub>]aryl, or independently the same as R<sup>6</sup>;

**(b)** wherein R<sup>6</sup> is

- (1) hydrogen, alkyl (which may be substituted by alkoxycarbonyl)-, alkenyl, alkynyl, cyano-, cyanoalkyl-, or Rs, wherein Rs is a [C<sub>6</sub> or C<sub>10</sub>]aryl or a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or
- (2) a group of the formula  $-W-R^7$  [as preferred in one embodiment], wherein  $R^7$  is alkyl, alkoxy, hydroxy, or Rs [as preferred in one embodiment], wherein W is -C(=O)- or  $-S(O)_2$ -;

(3) a group of the formula -W-OR<sup>8</sup> wherein R<sup>8</sup> is hydrogen or alkyl,

(4) a group of the formula -CH(OH)Rs; or

(5) a group of the formula  $-W-N(R^9)R^{10}$ , wherein

(a) R<sup>9</sup> is hydrogen and R<sup>10</sup> is an alkyl or cycloalkyl, optionally substituted; or

(b) R<sup>9</sup> is hydrogen or alkyl and R<sup>10</sup> is Ar\*; or

(c) R<sup>9</sup> is hydrogen or alkyl, R<sup>10</sup> is a heterocycle containing 4-10 ring atoms of which 1-3 are heteroatoms are selected from the group consisting of oxygen, nitrogen and sulfur; or

(d) R<sup>9</sup> and R<sup>10</sup> are both alkyl groups; or

(e) R<sup>9</sup> and R<sup>10</sup> together with N form a heterocycle containing 4-10 ring atoms which can incorporate up to one additional





heteroatom selected from the group of N, O or S in the ring, wherein the heterocycle is optionally substituted; or (f) R<sup>9</sup> and R<sup>10</sup> are both hydrogen; or

2.  $-NH_2$ , and

- 5 **e.** X is a pharmaceutically acceptable anion, which may be absent if the compound provides a neutralizing salt, or
  - (B) a pharmaceutically acceptable salt of the compound.

... the passe passe with the first the the track that the track the track that th